United States-based ANI Pharmaceuticals, Incorporated (Nasdaq:ANIP) has launched its Mexiletine Hydrochloride Capsules USP, 150mg, 200mg and 250mg, it was reported on Tuesday.
The product is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia.
Patrick Walsh, ANI's interim president and CEO, said, 'This is our sixth generic product launch in 2020. The launch represents an important milestone for ANI in the integration of our Oakville, Canada manufacturing site, acquired in August 2018. Mexiletine is the first new ANI product launch from the Oakville site. I congratulate the team in Oakville on achieving this milestone; we look forward to additional ANI product launches from this plant in the future.'
Piramal Pharma Solutions announces MSA for Plus Therapeutics' RNL-liposome intermediate drug product
Modus Therapeutics names new CFO
Mayne Pharma launches generic ORTHO-CEPT tablet in US
Amneal wins FDA approval for generic Ortho Evra, with 180 days of exclusivity pathway
Campanelli Named to Slayback Board of Directors
Dr. Reddy's Laboratories Launches Lansoprazole DR Orally Disintegrating Tablets in the US Market
Dr. Reddy's Laboratories Launches Capecitabine Tablets, USP in the US Market
Dr Reddy's Laboratories launches Fluphenazine Hydrochloride Tablets, USP in US antipsychotic market
Akorn Operating's Loteprednol Etabonate Ophthalmic Gel, 0.5% receives US FDA approval
Dr. Reddy's Laboratories Launches Vigabatrin Tablets, USP in the US Market
Dr. Reddy's Laboratories unveils Vigabatrin Tablets, USP in the US Market
Sandoz introduces generic Icatibant injection pre-filled syringe in US